HCA Forecast, price target & analysts
HCA Target price 2026 - Analyst rating & recommendation
HCA Classifications & Recommendation
HCA Price Target
| Target Price | $451.35 |
| Price | $423.48 |
| Potential |
6.58%
register free of charge
|
| Number of Estimates | 23 |
|
23 Analysts have issued a price target HCA 2027 .
The average HCA target price is $451.35.
This is
6.58%
register free of charge
$607.95
43.56%
register free of charge
$383.80
9.37%
register free of charge
|
|
| A rating was issued by 30 analysts: 17 Analysts recommend HCA to buy, 12 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the HCA stock has an average upside potential 2027 of
6.58%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 75.60 | 79.31 |
| 7.08% | 4.91% | |
| EBITDA Margin | 20.49% | 20.01% |
| 4.37% | 2.33% | |
| Net Margin | 8.97% | 8.19% |
| 9.99% | 8.73% |
26 Analysts have issued a sales forecast HCA 2026 . The average HCA sales estimate is
This results in the following potential growth metrics:
26 Analysts have issued an HCA EBITDA forecast 2026. The average HCA EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
26 HCA Analysts have issued a net profit forecast 2026. The average HCA net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 28.33 | 29.80 |
| 28.77% | 5.19% | |
| P/E | 14.21 | |
| EV/Sales | 1.77 |
26 Analysts have issued a HCA forecast for earnings per share. The average HCA EPS is
This results in the following potential growth metrics and future valuations:
Current HCA Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Leerink Partners |
Locked
➜
Locked
|
Locked | Sep 18 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 20 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Jul 28 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | Jul 28 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Jul 27 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Sep 18 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 20 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 03 2026 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Jul 28 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Jul 28 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Jul 27 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
